Trastuzumab-related cardiotoxicity among older patients with breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 33, 2013, Pages 4222-4228

  Chavez MacGregor, Mariana ^a   Zhang, Ning ^a   Buchholz, Thomas A ^a   Zhang, Yufeng ^a   Niu, Jiangong ^a   Elting, Linda ^a   Smith, Benjamin D ^a   Hortobagyi, Gabriel N ^a   Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; AGING; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CARDIOTOXICITY; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HEALTHCARE COMMON PROCEDURE CODING SYSTEM; HUMAN; HYPERTENSION; ICD-9; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; HEART FAILURE; KAPLAN MEIER METHOD; PATHOLOGY; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; STATISTICS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MEDICARE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 84892845082     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.7884     Document Type: Article

References (45)

1. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356, 2001 (Pubitemid 32366985)
2. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
3. Ravdin PM, Chamness GC: The c-erbB-2 protooncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review. Gene 159:19-27, 1995
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
5. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
7. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
8. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7:153, 2007
9. Yeh ET, Bickford CL: Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53: 2231-2247, 2009
10. Ewer MS, O'Shaughnessy JA: Cardiac toxicity of trastuzumab-related regimens in HER2- overexpressing breast cancer. Clin Breast Cancer 7:600-607, 2007 (Pubitemid 47028508)
11. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
12. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002 (Pubitemid 34177427)
13. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859- 3865, 2007 (Pubitemid 47477261)
14. Tripathy D, Slamon DJ, Cobleigh M, et al: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22:1063-1070, 2004 (Pubitemid 41095039)
15. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
16. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002 (Pubitemid 34111379)
17. Joensuu H, Bono P, Kataja V, et al: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 27: 5685-5692, 2009
18. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30: 3792-3799, 2012
19. Spielmann M, Roché H, Delozier T, et al: Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134, 2009
20. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
21. Guarneri V, Lenihan DJ, Valero V, et al: Longterm cardiac tolerability of trastuzumab in metastatic breast cancer: The MD Anderson Cancer Center experience. J Clin Oncol 24:4107-4115, 2006 (Pubitemid 46622286)
22. McArthur HL, Chia S: Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 357:94-95, 2007
23. Chen J, Long JB, Hurria A, et al: Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504-2512, 2012
24. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293- 1305, 2012
25. Du XL, Xia R, Burau K, et al: Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol 28:S80-S90, 2011 (suppl 1)
26. Tarantini L, Gori S, Faggiano P, et al: Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: A multicenter cohort analysis. Ann Oncol 23:3058-3063, 2012
27. Russell SD, Blackwell KL, Lawrence J, et al: Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28:3416-3421, 2010
28. Society AC: Breast Cancer Facts and Figures 2011-2012.
29. Hellman S: Stopping metastases at their source. N Engl J Med 337:996-997, 1997 (Pubitemid 27425957)
30. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
31. Comparative Effectiveness Research on Cancer: Comparative Effectiveness Research on Cancer in Texas. www.txcercit.org
32. Goff DC Jr, Pandey DK, Chan FA, et al: Congestive heart failure in the United States: Is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 160:197-202, 2000 (Pubitemid 30054339)
33. Lee DS, Donovan L, Austin PC, et al: Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 43:182-188, 2005 (Pubitemid 40222637)
34. Rosamond WD, Chang PP, Baggett C, et al: Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: A comparison of diagnostic criteria. Circ Heart Fail 5:152-159, 2012
35. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987 (Pubitemid 17055592)
36. Romano PS, Roos LL, Jollis JG: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 46:1075-1079, 1993
37. Guglin M, Hartlage G, Reynolds C, et al: Trastuzumab-induced cardiomyopathy: Not as benign as it looks? A retrospective study. J Card Fail 15:651-657, 2009
38. Pinder MC, Duan Z, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007 (Pubitemid 47477254)
39. Tarantini L, Cioffi G, Gori S, et al: Trastuzumab adjuvant chemotherapy and cardiotoxicity in realworld women with breast cancer. J Card Fail 18: 113-119, 2012
40. Leyland-Jones B: Dose scheduling: Herceptin. Oncology 61:31-36, 2001 (suppl 2)
41. Leyland-Jones B, Gelmon K, Ayoub JP, et al: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971, 2003 (Pubitemid 46606210)
42. Baselga J, Carbonell X, Castañeda-Soto NJ, et al: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162-2171, 2005 (Pubitemid 46218708)
43. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005 (Pubitemid 46211501)
44. Yood MU, Wells KE, Alford SH, et al: Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy. Pharmacoepidemiol Drug Saf 21:818-827, 2012
45. Hammond ME, Hayes DF, Wolff AC: Clinical notice for American Society of Clinical Oncology- College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 29:e458, 2011